Inhibition of cell migration and invasion mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor.

Détails

Ressource 1Télécharger: 5_24213569_Postprint.pdf (2819.84 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_9FE52CEBB707
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Inhibition of cell migration and invasion mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor.
Périodique
Oncogene
Auteur(s)
Barras D., Lorusso G., Rüegg C., Widmann C.
ISSN
1476-5594 (Electronic)
ISSN-L
0950-9232
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
33
Numéro
44
Pages
5163-5172
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
TAT-RasGAP317-326, a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration and inhibit matrix invasion. This is accompanied by a marked modification of the actin cytoskeleton and focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are well-characterized proteins modulating actin fibers, adhesion and migration, do not appear to be required for the pro-adhesive properties of TAT-RasGAP317-326. In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP317-326 to promote cell adherence and inhibit migration. These results show that TAT-RasGAP317-326, besides its ability to favor tumor cell death, hampers cell migration and invasion.
Pubmed
Web of science
Open Access
Oui
Création de la notice
02/12/2014 18:00
Dernière modification de la notice
20/08/2019 15:06
Données d'usage